Kohn's
gene therapy approach using HSC from patient's own blood is a revolutionary
alternative to current SCD treatments as it creates a self - renewing normal blood cell by inserting a
gene that has anti-sickling properties into HSC.
Activators of histone acetyltransferases (HAT) provide an
alternative approach for the selective activation of
gene expression, however little is known about the potential of HAT activators as drug
therapies for PD.